Pharmaceutical Market Europe • January 2026 • 36
APPOINTMENTS
Gilead
Keeley Wettan
Gilead has appointed Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance. She is also currently Chair of the Board of the Gilead Foundation. During her 14 years at Gilead, Wettan has held a variety of increasingly senior leadership roles. She was previously Senior Vice President, leading the Global Legal Business Partners team. Prior to that, she led the Litigation and Government Investigations and the Corporate Governance and Strategic Transactions teams. Wettan has provided instrumental support in a variety of drug launches at Gilead, including the recent launch of the breakthrough HIV prevention medicine lenacapavir. In her new role, she will join the company’s senior leadership team. Before joining Gilead, Wettan was an attorney at Simpson Thacher & Bartlett.
Slingshot Therapeutics
John Isaac
Slingshot Therapeutics has appointed
John Isaac as Chief Scientific Officer (CSO). Isaac recently served as CSO of AviadoBio. His other previous roles include Head of Neuroscience, External Innovation, Europe, the Middle East and Africa (EMEA) at Johnson & Johnson; Head of Neuroscience at Wellcome, and Head of Neurophysiology at Eli Lilly.
Eli Lilly
Carole Ho
Eli Lilly has appointed Carole Ho as President of its neuroscience division. Ho brings extensive pharmaceutical experience to the role, having previously served as Chief Medical Officer of Denali Therapeutics. She serves as a Board member at a variety of companies, including Royalty Pharma, Beam Therapeutics and, previously, NGM Biopharmaceuticals.
Sonoma Biotherapeutics
Stephen Dilly
Sonoma Biotherapeutics has appointed
Stephen Dilly as CEO. Dilly was previously CEO at Codexis, where he spent over five years, and will continue to serve as the company’s Board Chair. Dilly’s earlier roles include CEO of Sierra Oncology, Aimmune Therapeutics and PhotoThera, and as a board member at Cognoa and Adjuvance Technologies.
Domain Therapeutics
Jean-Marie Cuillerot
Domain Therapeutics has appointed
Jean-Marie Cuillerot as Chief Medical Officer (CMO). He has held the role of CMO at companies including Acrivon Therapeutics, Dragonfly Therapeutics and Agenus. Other previous roles include Global Head of Clinical Development in Immuno-Oncology and Vice President of Clinical Immunotherapy /Immuno-Oncology at EMD Serono.
Eli Lilly
Carolyn Bertozzi
Eli Lilly has appointed Carolyn Bertozzi to its Board of Directors. Bertozzi previously served on Lilly’s board from 2017 to 2021; she is an elected member of the National Academy of Medicine, National Academy of Sciences and American Academy of Arts and Sciences, and received the 2022 Nobel Prize in Chemistry.
Enhanced Genomics
Katerina Leftheris
Enhanced Genomics has appointed Katerina Leftheris to its Board of Directors. She was previously Chief Scientific Officer at Vilya. Her other roles include Associate Director of Chemistry at Bristol Myers Squibb and Senior Director Chemistry at Celgene. Leftheris sits on the Board of Directors and Scientific Advisory Boards of various biotechnology companies.
Incyclix Bio
Kimberly Blackwell
Incyclix Bio has appointed
Kimberly Blackwell to its Board of Directors. She is Chief Development Officer at Nucleus RadioPharm and founded Key Oncology Consulting, guiding biotechnology companies in the field of precision oncology. She has held senior leadership roles at companies including Zentalis Pharmaceuticals, Tempus AI and Eli Lilly.
CNX Therapeutics
Kevan Leggett
CNX Therapeutics has appointed
Kevan Leggett as Chair. Leggett brings over 25 years of expertise in both private equity and corporate finance to the role through his extensive work as a Mergers and Acquisitions advisor. Since 2010, he has served on the boards of more than 15 private equity-backed businesses.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services